Welcome to Vayuna Therapeutics
A Comprehensive ADC Platform Addressing EGFR High Treatment-Resistant Cancer
Multiple modalities. 70+ targets. One differentiated payload.
Vayuna Therapeutics is building the next generation of antibody-drug conjugates using nature-derived compounds with differentiated drug resistance profiles. Lead indication: EGFR High Triple Negative Breast Cancer (TNBC).
FIRST-IN-CLASS
Next-Generation Precision ADCs
and Parenteral Formulations with V-001
for EGFR High
& Treatment-Resistant Cancers
THE PROBLEM
Treatment Resistance in Cancer — EGFR High Triple Negative Breast Cancer is Key Unmet Need
Limited Effective Therapies
For treatment-resistant solid tumors.
P-gp Drug Efflux
40–70% of resistant tumors overexpress P-glycoprotein.
Imprecise Treatments
Result in suboptimal outcomes and significant toxicity.
“EGFR High” expression occurs in 30–45% of breast cancers and up to 80% of solid tumors, while PIK3CA mutations appear in 30–40% of breast cancers and 10–15% of all cancers.
the solution
A Platform, Not Just a Product
Validated Targets
Comprehensive IP covering major tumor-associated antigens including EGFR, HER2, TROP-2, Nectin-4, PD-L1, B7-H3, PSMA, CD19, CD33 and more.
Multiple Modalities
Monospecific ADCs, Bispecific ADCs, and Ligand-Drug Conjugates — providing multiple shots on goal against resistance.
Proprietary Linker Tech
High drug-to-antibody ratio formulations enabling superior payload delivery through proprietary linker chemistries.
Drug Resistance Focus
Payload modulates P-glycoprotein without being a substrate — unlike most competing ADC payloads on the market.
